These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18727638)

  • 1. The blood-brain barrier in migraine treatment.
    Edvinsson L; Tfelt-Hansen P
    Cephalalgia; 2008 Dec; 28(12):1245-58. PubMed ID: 18727638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The triptans.
    Bigal ME; Krymchantowski AV; Hargreaves R
    Expert Rev Neurother; 2009 May; 9(5):649-59. PubMed ID: 19402776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
    Edvinsson L; Warfvinge K
    Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental migraine models and their relevance in migraine therapy.
    Arulmani U; Gupta S; VanDenBrink AM; Centurión D; Villalón CM; Saxena PR
    Cephalalgia; 2006 Jun; 26(6):642-59. PubMed ID: 16686903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finding new drug targets for the treatment of migraine attacks.
    Olesen J; Tfelt-Hansen P; Ashina M
    Cephalalgia; 2009 Sep; 29(9):909-20. PubMed ID: 19250288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
    Edvinsson L
    Br J Clin Pharmacol; 2015 Aug; 80(2):193-9. PubMed ID: 25731075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache.
    Olesen J
    Pharmacol Ther; 2008 Nov; 120(2):157-71. PubMed ID: 18789357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine.
    Levy D; Burstein R; Strassman AM
    Ann Neurol; 2005 Nov; 58(5):698-705. PubMed ID: 16240341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
    Gupta S; Villalón CM
    Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine.
    Gupta VK
    Expert Rev Neurother; 2009 Nov; 9(11):1595-614. PubMed ID: 19903020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine: new treatment options from molecular biology.
    Stam AH; Haan J; Frants RR; Ferrari MD; van den Maagdenberg AM
    Expert Rev Neurother; 2005 Sep; 5(5):653-61. PubMed ID: 16162089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What have we learnt from triggering migraine?
    Schytz HW; Schoonman GG; Ashina M
    Curr Opin Neurol; 2010 Jun; 23(3):259-65. PubMed ID: 20173638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new therapeutic principle for migraine].
    Ashina M; Jensen RH
    Ugeskr Laeger; 2008 Mar; 170(12):1029. PubMed ID: 18397647
    [No Abstract]   [Full Text] [Related]  

  • 14. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
    Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
    Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic mechanisms of migraine and its acute treatment.
    Edvinsson L; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2012 Dec; 136(3):319-33. PubMed ID: 22939884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier.
    Cheng Z; Liu H; Yu N; Wang F; An G; Xu Y; Liu Q; Guan CB; Ayrton A
    Xenobiotica; 2012 Sep; 42(9):880-90. PubMed ID: 22509823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.
    Chan KY; Vermeersch S; de Hoon J; Villalón CM; Maassenvandenbrink A
    Pharmacol Ther; 2011 Mar; 129(3):332-51. PubMed ID: 21130807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP antagonists: unravelling the role of CGRP in migraine.
    Doods H; Arndt K; Rudolf K; Just S
    Trends Pharmacol Sci; 2007 Nov; 28(11):580-7. PubMed ID: 17963849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal signal substances as biomarkers of migraine.
    Edvinsson L
    Headache; 2006; 46(7):1088-94. PubMed ID: 16866713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of migraine headache in the emergency department.
    Robertson CE; Black DF; Swanson JW
    Semin Neurol; 2010 Apr; 30(2):201-11. PubMed ID: 20352590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.